Amgen and AstraZeneca report positive lung cancer trial results
Amgen and AstraZeneca reported positive results from a lung-cancer trial. The immediate setup is therefore event-driven but unquantified, with the commercial significance for AMGN and AZN still unproven.
STOCK PHOTO · STEPHEN LEONARDIThe story
Investing.com reported on September 9 that Amgen and AstraZeneca had positive results from a lung-cancer trial.
The companies enter the news with different reported business scales: Amgen recorded $36.8B of revenue and $14.23 in diluted EPS for FY 2025, while AstraZeneca reported $58.7B of revenue, $6.54 in diluted EPS and a 17.4% net margin for the same annual period. Those figures establish the companies’ existing businesses, but they do not quantify any contribution from this trial.
For Amgen, the mechanism would be a successful lung-cancer program adding to future product revenue and pipeline value; for AstraZeneca, the result would connect to an oncology business already represented in its broader revenue base.
The positive characterization is not supported by trial-level figures in the report. There is no disclosed hazard ratio, response rate, survival result, adverse-event profile or regulatory commitment, leaving the size and durability of the clinical benefit uncertain.
The next decisive evidence would be the companies’ full trial disclosures, a conference presentation or a regulatory filing that identifies the endpoint and safety data. Until those details are released, the headline supports recognition of a potentially favorable clinical update but not a quantified earnings or valuation read.
Our read · Wed, Sep 9
AMGN and AZN have a potentially positive oncology catalyst, but the undisclosed trial endpoints leave the commercial read unquantified.
Why. AMGN’s FY 2025 revenue was $36.8B and AZN’s was $58.7B, so the headline alone cannot show material near-term earnings impact.
Both cases
What could change this view: The positive description could prove immaterial if the full results show a modest benefit, meaningful safety issues, unclear statistical significance or no near-term regulatory path.
Who reported it · 1
Since this story · the companies named here, equal weight · +12.0%
Price context does not establish that the story caused the move.
Keep reading
More on AMGN
Amgen, Novartis decline on disappointing clinical trial results; details not disclosedLatest on the Wire
Greer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultAnthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeContinue on the Wire →Latest on the Wire
US MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesChina seeks protections to restart US private-equity investmentsContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by Investing.com, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →